Categories: News

Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit

MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) — Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET.

A live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

Staff

Recent Posts

Healthcare Payer IT in 2026: Digital Prior Authorization, Enforceable Transparency, and Outcomes-Driven Platforms Spark a New Acquisition Race

CMS compliance deadlines and heightened cybersecurity expectations are accelerating payer interoperability and utilization management modernization…

3 hours ago

New National Alliance Launches to Address Health Workforce Shortages in Underserved Communities

WASHINGTON, D.C. / ACCESS Newswire / December 15, 2025 / Leading national organizations have come…

6 hours ago

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA…

6 hours ago

TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent

HighlightsNewly granted patent protects TempraMed's VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architectureExpands the…

7 hours ago

Functional Brands Announces Third Quarter 2025 Financial Results

Lake Oswego, Oregon--(Newsfile Corp. - December 15, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a…

7 hours ago